

11-01-04

1624
C/10/B

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/071,978
	Filing Date	February 6, 2002
	First Named Inventor	Eric E. Swayze
	Art Unit	1624
	Examiner Name	K. Habte
Total Number of Pages in This Submission	Attorney Docket Number	ISIC0055-100 (IBIS-0403US)

ENCLOSURES (check all that apply)				
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO SB/08b (2 pp); Copies of (11) Cited References; and, Copy of Int'l Search Report dated July 28, 2004 for Int'l Appln. No. PCT/US03/38093.		
<table border="1"><tr><td>Remarks</td><td>Express Mail Label No: EV 147591127 US Date of Deposit: October 28, 2004 EV147591127US</td></tr></table>			Remarks	Express Mail Label No: EV 147591127 US Date of Deposit: October 28, 2004 EV147591127US
Remarks	Express Mail Label No: EV 147591127 US Date of Deposit: October 28, 2004 EV147591127US			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Gwilym J. O. Attwell, Registration No. 45,449
Signature	
Date	October 28, 2004

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



ISIC055-100 (IBIS-0403US)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: **Swayze, Seth, Griffey and Jefferson**

Serial No.: **10/071,978**

Group Art Unit: **1624**

Filing Date: **February 6, 2002**

Examiner: **K. Habte**

For: **Novel Benzimidazole Compounds**

Express Mail Label No: EV 147591127 US

Date Of Deposit: October 28, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08b, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits. Applicants note that each reference in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.
- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
- or**
- ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- ☒ Copies of References cited on the attached PTO Form SB/08b, formerly known as PTO Form 1449 is enclosed. Also enclosed is a copy of the International Search Report dated July 28, 2004 for International Application No. PCT/US03/38093.

EXCEPT THAT:

- ☐ In view of the voluminous nature of reference @@@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.


Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees


- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,


Gwilym J.O. Attwell
Registration No. 45,449

Dated: October 28, 2004

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 701-2013 - Facsimile



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/729,189
Filing Date	December 8, 2003
First Named Inventor	Eric E. Swayze
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	ISIC0055-100 (IBIS-0403)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	FRETER et al., Database CAPLUS on STN (Columbus, OH, USA), No. 98:160710, "Substituted n-(4-indolyl)piperidinoalkyl benzimidazolones and their use as pharmaceutical preparations," 1983, abstract, EP 58975, see RN 84461-75-6.	
	AE	FONQUERNA et al., Database CAPLUS on STN (Columbus, OH, USA), No. 136:369609, "Preparation of indolylpiperidines as antihistaminic and antiallergic agents," 2002, WO 2002-036589, see RN 423174-70-3 etc.	
	AF	EDWARDS, Database CAPLUS on STN (Columbus, OH, USA), No. 79:18714, "Imidazole derivatives," 1973, abstract, DE 2259345, see RN 42032-10-0 and 42032-11-1.	
	AG	TEUBER et al., Database CAPLUS on STN (Columbus, OH, USA), No. 132:93320, "Preparation of aminobenzimidazoles and guanidines as novel potassium channel blocking agents," 2000, WO 2000-001676, see RN 83750-38-3 etc.	
	AH	AGAI et al., Database CAPLUS on STN (Columbus, OH, USA), No. 85:78096, "Condensed 1,3,5-triazepines. III. Derivatives of 4,5-dihydro-[1,3,5]triazepino[1,2-a]benzimidazole," <i>Tetrahedron</i> 1976, Vol. 32, No. 7, pp. 839-842, abstract, see RN 60078-74-2 and 60078-75-3 etc.	
	AI	OGRUA et al., Database CAPLUS on STN (Columbus, OH, USA), No. 77:160002, "Heterocyclic Compounds. 10. Synthesis of some imidazo[1,2-a]benzimidazoles with potent analgetic activities," <i>Journal Of Medicinal Chemistry</i> , 1972, Vol. 15, No. 9, pp. 923-926, abstract, see RN 38652-78-7 etc.	
	AJ	SARETT et al., Database CAPLUS on STN (Columbus, OH, USA), No. 56:79451, "Benzimidazoles carrying thiazolyl, thiadiazolyl, and isothiazolyl substituents in the 2-position," 1962, US 3017415, abstract, see RN 91843-61-7.	
	AK	MERCK & CO., Database CAPLUS on STN (Columbus, OH, USA), No. 62:15351, "Substituted Benzimidazoles," 1964, GB 866796, abstract, see RN 4048-07-1.	
	AL	E.R. SQUIBB AND SONS, INC., Database CAPLUS on STN (Columbus, OH, USA), No. 82:156304, "Pridyl-1H-Benzimidazole N-Oxide," 1975, abstract, US 3864350, see RN 55396-67-3.	
	AM	WARNER LAMBERT CO., Database CAPLUS on STN (Columbus, OH, USA), No. 108:131822, "Preparation and testing of antiarteriosclerotic substituted benzimidazol-2-yl- and 3H-imidazo[4,5-b]pyridine-2-ylphenoxyalkanoic acids and their salts and esters," 1988, US 4714762, abstract, see RN 113561-63-0.	
	AN	AVENTIS PHARMACEUTICALS PRODUCTS INC., Database CAPLUS on STN (Columbus, OH, USA), No. 135:344381, "Preparation of 1-aryl-piperidinyl benzamides as inhibitors of factor Xa or trypsin," 2001, WO 2001-081310, abstract, see RN 370864-68-9.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

<i>Application Number</i>	10/729,189
<i>Filing Date</i>	December 8, 2003
<i>First Named Inventor</i>	Eric E. Swayze
<i>Art Unit</i>	To Be Determined
<i>Examiner Name</i>	To Be Determined
<i>Attorney Docket Number</i>	ISIC0055-101 (IBIS-0033US)

NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.